• The Company recently announced reaching a record $13 million annualized revenue run rate in April 2023

REDWOOD CITY, CA / ACCESSWIRE / June 26, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, announced that it will host its Fiscal Year 2023 Financial Results and Business Update Call on Friday, June 30, 2023. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.

Event: Biotricity FY 2023 Financial Results and Business Update Call
Date: Friday, June 30th
Time: 4:30pm ET (1:30pm PT)

Toll Free: 877-405-1216
International: +1 201-689-8336
Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=HhUoTP8T

Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. To submit a question for management, please email This email address is being protected from spambots. You need JavaScript enabled to view it. by end of day on June 27^th.

A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at https://www.biotricity.com/investors/.

Toll Free Replay Number: 877-660-6853
International: 201-612-7415
Replay Access ID: 13739462
Expiration: July 14, 2023, 11:59 PM ET

In May 2023, the Company announced that it reached a record $13 million annualized revenue run rate in April -- further extending its growth by over eight percent from the $12 million run rate it announced for March 2023.

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended December 31, 2022 the Company incurred a net loss attributable to common stockholders of $4.74 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts

Investor Relations
Biotricity Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.